ReviewFrontiers in pharmacology2022
Natural Compounds: A Hopeful Promise as an Antibiofilm Agent Against
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 51 citations in OpenAlex.
- From Antimicrobial Activity to Topical Translation: An Integrated Framework for Testing, Cytotoxicity Assessment and Formulation of Plant Extracts, Essential Oils and Honey.Pharmaceutics · 2026Review
- Evaluation of the Antifungal Efficacy of Natural Gum Acacia and Aloe Vera against Candida albicans on Conventional and Digital Denture Base Materials: An In Vitro Study.European journal of dentistry · 2026Article
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- Carvacrol Reduces Virulence Traits inMicroorganisms · 2026Article
- Natural-Compound Adjuvants Dismantle Candida Biofilms: Mechanisms, Design Rules, and Biofilm-Aware Pharmacology.Current microbiology · 2026Review
- Article
- Bioactive Constituents ofDrug design, development and therapy · 2026Review
- Inhibitory effect and safety of Angelica dahurica-Ligusticum sinense extracts against Malassezia furfur and its biofilms.PloS one · 2026Article
- Molecular mechanisms, pathogenesis and therapeutic advances ofFrontiers in cellular and infection microbiology · 2026Review
- Natural product based approaches to overcomeFrontiers in antibiotics · 2026Review
- Essential oils as nature-engineered antifungals: a comprehensive review of pharmacological mechanisms, drug synergism, and advanced formulation strategies.Frontiers in pharmacology · 2026Review
- TargetingInternational journal of molecular sciences · 2025Article
- Emerging Multimodal Strategies for Bacterial Biofilm Eradication: A Comprehensive Review.Microorganisms · 2025Review
- Chitosan nanoparticles loaded with ribavirin, carboplatin, and thyme oil downregulate SNQ2, ERG11, CDR1, and MDR1 in Candida strains.Scientific reports · 2025Article
- In Silico and In Vitro Potential Antifungal Insights of Insect-Derived Peptides in the Management ofInternational journal of molecular sciences · 2025Article
- The possible pathogenic mechanisms of microorganisms in infertility: a narrative review.Archives of microbiology · 2025Review
- Natural compounds: new therapeutic approach for inhibition ofFrontiers in pharmacology · 2025Review
- Exploring the Antibiofilm Effect of Sertraline in Synergy withPharmaceuticals (Basel, Switzerland) · 2024Article
- Platelet-derived biomaterial controls aspergillus fumigatus keratitis by decreasing fungal burden: an in vivo study.Archives of microbiology · 2024Article
- Surfactants' Interplay with Biofilm Development inPharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biofilm communities of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.